Who are CC-5013 (Revlimid™)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lenalidomide Oral Capsule, R2: Lenalidomide plus placebo maintenance, Lenalidomide (Control), Lenalidomide PO (25mg).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cc-5013-revlimid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CC-5013 (Revlimid™) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CC-5013 (Revlimid™) (CC-5013 (Revlimid™)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent (IMiD). Area: Oncology.

phase 3 Immunomodulatory agent (IMiD) Cereblon (CRBN) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CC-5013 (Revlimid™) (CC-5013 (Revlimid™)) — University of Arkansas. CC-5013 (lenalidomide) is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while inhibiting TNF-α and IL-6 production, and also has direct anti-angiogenic and anti-proliferative effects on tumor cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CC-5013 (Revlimid™) TARGET	CC-5013 (Revlimid™)	University of Arkansas	phase 3	Immunomodulatory agent (IMiD)	Cereblon (CRBN)
Lenalidomide Oral Capsule	Lenalidomide Oral Capsule	The First Affiliated Hospital with Nanjing Medical University	phase 3	Immunomodulatory agent (IMiD)	Cereblon (CRBN)
R2: Lenalidomide plus placebo maintenance	R2: Lenalidomide plus placebo maintenance	University of Leeds	phase 3	Immunomodulatory agent (IMiD)	Cereblon (CRBN)
Lenalidomide (Control)	Lenalidomide (Control)	University of Chicago	phase 3	Immunomodulatory agent (IMiD)	Cereblon (CRBN)
Lenalidomide PO (25mg)	Lenalidomide PO (25mg)	University Hospital, Lille	phase 3	Immunomodulatory agent (IMiD)	Cereblon (CRBN)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent (IMiD) class)

The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
University Hospital, Lille · 1 drug in this class
University of Arkansas · 1 drug in this class
University of Chicago · 1 drug in this class
University of Leeds · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CC-5013 (Revlimid™) — Competitive Intelligence Brief. https://druglandscape.com/ci/cc-5013-revlimid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing